JP2024521164A5 - - Google Patents

Info

Publication number
JP2024521164A5
JP2024521164A5 JP2023572868A JP2023572868A JP2024521164A5 JP 2024521164 A5 JP2024521164 A5 JP 2024521164A5 JP 2023572868 A JP2023572868 A JP 2023572868A JP 2023572868 A JP2023572868 A JP 2023572868A JP 2024521164 A5 JP2024521164 A5 JP 2024521164A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
day
teprizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030780 external-priority patent/WO2022251258A1/en
Publication of JP2024521164A publication Critical patent/JP2024521164A/ja
Publication of JP2024521164A5 publication Critical patent/JP2024521164A5/ja
Pending legal-status Critical Current

Links

JP2023572868A 2021-05-24 2022-05-24 感染後自己免疫性糖尿病を治療するための方法 Pending JP2024521164A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163192414P 2021-05-24 2021-05-24
US63/192,414 2021-05-24
PCT/US2022/030780 WO2022251258A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes
US17/752,650 US20220372146A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes
US17/752,650 2022-05-24

Publications (2)

Publication Number Publication Date
JP2024521164A JP2024521164A (ja) 2024-05-28
JP2024521164A5 true JP2024521164A5 (cg-RX-API-DMAC7.html) 2025-11-05

Family

ID=84104472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572868A Pending JP2024521164A (ja) 2021-05-24 2022-05-24 感染後自己免疫性糖尿病を治療するための方法

Country Status (10)

Country Link
US (1) US20220372146A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347021A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521164A (cg-RX-API-DMAC7.html)
KR (1) KR20240023522A (cg-RX-API-DMAC7.html)
CN (1) CN117794572A (cg-RX-API-DMAC7.html)
AU (1) AU2022283272A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219473A1 (cg-RX-API-DMAC7.html)
IL (1) IL308627A (cg-RX-API-DMAC7.html)
MX (1) MX2023013849A (cg-RX-API-DMAC7.html)
WO (1) WO2022251258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20230382993A1 (en) * 2022-05-24 2023-11-30 Provention Bio, Inc. Methods and compositions for preventing or delaying type 1 diabetes
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
JP2009544761A (ja) * 2006-06-14 2009-12-17 マクロジェニクス,インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
JP7137696B2 (ja) * 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
WO2021035054A1 (en) * 2019-08-20 2021-02-25 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
KR20230092863A (ko) * 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) * 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20230382993A1 (en) * 2022-05-24 2023-11-30 Provention Bio, Inc. Methods and compositions for preventing or delaying type 1 diabetes

Similar Documents

Publication Publication Date Title
Kitabchi et al. The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis
Jones et al. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes
Schmeltz et al. Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia
Inagaki et al. Efficacy and safety of canagliflozin alone or as add‐on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52‐week open‐label study
JP6367115B2 (ja) 2型糖尿病患者の血糖コントロールに使用する組合せ医薬
Meneghini Early insulin treatment in type 2 diabetes: what are the pros?
Frandsen et al. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomized, placebo‐controlled, double‐blind, parallel‐group study
CN105142661B (zh) 通过长效胰岛素制剂治疗糖尿病
JP2024520444A5 (cg-RX-API-DMAC7.html)
CN103648520A (zh) 用于诱导ii型糖尿病患者体重减轻或者/和用于防止ii型糖尿病患者体重增加的药物组合产品
JP2014514356A (ja) 2型糖尿病の処置のためのリキシセナチド及びメトホルミン
CN103582491A (zh) 2型糖尿病患者中低血糖症的预防
JP2023002501A5 (cg-RX-API-DMAC7.html)
US20240245656A1 (en) Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
Lim et al. Effect of the concomitant use of subcutaneous basal insulin and intravenous insulin infusion in the treatment of severe hyperglycemic patients
Sprunt et al. Some aspects of the pharmacology of metyrapone
Frias et al. A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections
MX2011004189A (es) Uso de cloruro de amonio en terapia.
Akizawa et al. Dose‐finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double‐blind, randomized, placebo‐controlled and sevelamer hydrochloride‐controlled open‐label, parallel group study
Kurozumi et al. Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves’ disease and type 1 diabetes mellitus: a case report
Satomura et al. Clinical features resembling subcutaneous insulin resistance observed in a patient with type 2 diabetes and severe COVID-19-associated pneumonia: a case report
Ganda Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
Ferri et al. Salt-sensitivity is associated with a hyperinsulinaemic and hyperglycaemic response to atrial natriuretic peptide infusion in human essential hypertension
Gao et al. Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open‐label, phase 3 study
Hatano et al. Long-Term Efficacy and Safety of Add-On Therapy of Sitagliptin to a Very Small Dose of Glimepiride Versus a Small Dose of Glimepiride Over Eighteen Months